Objective: The aim of this study was to evaluate the combination effect of paclitaxel (PTX) and cisplatin (CDDP) and to determine the mechanisms of interaction between these agents. Methods and Results: We used human ovarian adenocarcinoma cell lines, namely a parent cell line (KF), a CDDP-resistant cell line (KFr) and a PTX-resistant cell line (KFTx).The combination effect of PTX and CDDP was synergistic on KF and KFTx and additive on KFr. The incidence of anaphase or telophase, evaluated by immunofluorescence microscopy, decreased with PTX and significantly decreased with PTX and CDDP in KF and KFTx. The concentration of PTX, which was measured by high-performance liquid chromatography, was higher in KF and KFTx cells treated with a combination of PTX and CDDP than those treated with PTX alone. Multidrug resistance gene mRNA appeared in KFTx and its expression decreased after exposure to PTX and CDDP. After exposure to CDDP, the expression of multidrug resistance-associated protein (MRP) and the concentration of glutathione increased in KF, but not in KFr or KFTx. MRP expression slightly increased in KF and KFTx after exposure to PTX. In contrast, its expression decreased in KFr. Conclusion: The present study suggests that CDDP enhances PTX accumulation and that the interaction of these agents is synergistic in CDDP-sensitive cells.

Keywords:
CDDP, Paclitaxel, Combination effect, MDR-1, MRP
1.
Parness J, Horwitz SB: Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91:479–487.
2.
Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134–136.
3.
Roberts JR, Allison DC, Donehower RC, Rowinsky EK: Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 1990;50:710–716.
4.
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.
5.
Neijt JP, Engelholm SA, Witteveen PO, Tuxen MK, Sorensen PG, Hansen M, Hirsch F, Sessa C, de Swart C, van Houwelingen HC, Lund B, Hansen SW: Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: An interim analysis. Semin Oncol 1997;24:36–39.
6.
Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654–2666.
7.
Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994;69:299–306.
8.
Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A, Gornati D, Villa R: Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer 1998;77:1378–1385.
9.
Judson PL, Watson JM, Gehrig PA, Fowler WC Jr, Haskill JS: Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: Possible explanation for failure of combination therapy. Cancer Res 1999;59:2425–2432.
10.
Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992;89:3070–3074.
11.
Kigawa J, Minagawa Y, Cheng X, Terakawa N: Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 1998;4:1737–1741.
12.
Lautier D, Canitrot Y, Deeley RG, Cole SP: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996;52:967–977.
13.
Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP: Taxol: Mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;55–61.
14.
Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
15.
Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y: Effects of (CPT-11) in combination with other anti-cancer agents in culture. Int J Cancer 1992;50:604–610.
16.
Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M: High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987;71:53–59.
17.
LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL, Litterst CL, Gram TE, Guarino AM, Becker DA: Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 1977;18:184–191.
18.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
19.
Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT: Coordinated induction of MRP/GS-X pump and γ -glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996;271:14981–14988.
20.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
21.
Owens CWI, Belcher RV: A colorimetric micro-method for the determination of glutathione. Biochem J 1965;94:705–711.
22.
Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M: In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 1997;75:869–877.
23.
Levasseur LM, Greco WR, Rustum YM, Slocum HK: Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 1997;40:495–505.
24.
Rowinsky EK, Donehower RC: Taxol: Twenty years later, the story unfolds. J Natl Cancer Inst 1991;83:1778–1781.
25.
Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB: In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 1993;92: 431–440.
26.
Santoni RE, Silverman JA: Functional characterization of the rat mdr1b encoded P-glycoprotein: Not all inducing agents are substrates. Carcinogenesis 1997;18:2255–2263.
27.
Ciaccio PJ, Shen H, Kruh GD, Tew KD: Effects of chronic ethacrynic acid exposure on glutathione conjugation and MRP expression in human colon tumor cells. Biochem Biophys Res Commun 1996;222:111–115.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.